A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.
Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.
Insufficient evidence exists to show efficacy of novel hypersensitivity pneumonitis therapies, indicating the need for clinical protocols.
Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.
Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...
Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...
Connect with our experts for FREE personalized support to help you manage COPD. Whether you are newly diagnosed or have been living with COPD for years, you can always learn something new. Read more ...
CO indicates cardiac output; mPAP, mean pulmonary artery pressure; PA, pulmonary artery; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results